Clinical Endocrinology (2003) **58**, 801–809

Index

Abucham, J. *see* Brunner, E.
Adamczewski, Z. *see* Dedecjus, M.
Ahlquist, J.A. *see* Fahie-Wilson, M.N.
Ahmad, A.M. *see* Diver, M.J.
Ahmad, A.M. *see* White, H.D.
Ahmed, S.F. *see* Wallace, A.M.
Aimaretti, G. *see* Grottoli, S.
Altomare, M. *see* Corsello, S.M.
Amato, G. *see* Sorvillo, F.
Amino, N. *see* Tada, H.
Anastasiadis, A.D. *see* Weissberger, A.J.
Anderson, R.A. *see* Brady, B.M.
Anderson, S.G. *see* Heald, A.H.
Angeli, A. *see* Reimondo, G.
Ansari, M.R. *see* Rao, D.S.
Antonelli, R.F. *see* Rao, D.S.
Araujo, K.L.B. *see* Sowers, M.
Arias, A.M.P. *see* Pluijmen, M.J.H.M.
Arnaldi, G. *see* Scillitani, A.
Arosio, M. *see* Scillitani, A.
Arvat, E. *see* Broglio, F.
Asscheman, H. *see* Elbers, J.M.H.
Assmann, G. *see* von Eckardstein, A.
Astorga, R. *see* Lucas, T.
Astrup, A. *see* Mersebach, H.
Attard, M. *see* Pellegriti, G.
Aversa, A., Isidori, A.M., Spera, G., Lenzi, A. & Fabbri, A. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction: 632
Baima, J. *see* Brunner, E.
Baird, D.T. *see* Brady, B.M.
Bakker, O. *see* Wakelkamp, I.M.M.J.
Baldelli, R. *see* Scillitani, A.
Baldeschi, L. *see* Terwee, C.B.
Baldeschi, L. *see* Wakelkamp, I.M.M.J.
Barkan, A.L. Radiotherapy in acromegaly: the argument against: 132
Barrett, P.H.R. *see* Dane-Stewart, C.A.
de Barros, J.-P.P. *see* Dedecjus, M.
Bassett, J.H.D. *see* Pannett, A.A.J.
Bath, L.E. *see* Crofton, P.M.
Battista, C. *see* Scillitani, A.
Baxter, R.C. *see* Frystyk, J.
Beauregard, C., Truong, U., Hardy, J. & Serri, O. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly: 86
Beckers, A. *see* Svensson, J.
Beckett, G.J. & Toft, A.D. First-line thyroid function tests – TSH alone is not enough: 20
Beguin, C. *see* Delporte, M.L.
Bell, J.R. *see* Jack, M.M.
Bengtsson, B.-Å. *see* Svensson, J.
Bennink, H.C. *see* von Eckardstein, A.
Benso, A. *see* Broglio, F.
Bergui, M. *see* Reimondo, G.
Besser, G.M. *see* Isidori, A.M.
Bex, M. *see* Svensson, J.
Biermasz, N.R., van den Oever, N.C., Frölich, M., Pereira Arias, A.M., Smit, J.W.A., Romijn, J.A. & Roelfsema, F. Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval: 288
Billeci, D. *see* Cannavò, S.
Blethen, S.L. *see* Rogol, A.D.
Boelaert, K. *see* McCabe, C.J.
Bonaduce, D. *see* Colao, A.
Bonsel, G.J. *see* Terwee, C.B.
Borsari, S. *see* Cetani, F.
Boson, W.L., Sarubi, J.C., D'Alva, C.B., Friedman, E., Faria, D., de Marco, L. & Wajchenberg, B. A signal peptide mutation of the arginine vasopressin gene in monozygotic twins: 108
Bradley, C. *see* McMillan, C.V.
Bradley, K.J., Wass, J.A.H. & Turner, H.E. Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumours but do not recur more frequently: 59
Brady, B.M., Anderson, R.A., Kinniburgh, D. & Baird, D.T. Demonstration of progesterone receptor-mediated gonadotrophin suppression in the human male: 506
Breen, L. *see* Christ, E.R.
Brichard, S.M. *see* Delporte, M.L.
Broglio, F., Gottero, C., Benso, A., Prodam, F., Casanueva, F.F., Dieguez, C., van der Lely, A.J., Deghenghi, R., Arvat, E. & Ghigo, E. Acetylcholine does not play a major role in mediating the endocrine responses to ghrelin, a natural ligand of the GH secretagogue receptor, in humans: 92
Brunner, E., Baima, J., Vieira, T.C., Vieira, J.G.H. & Abucham, J. Hereditary corticosteroid-binding globulin deficiency due to a missense mutation (Asp367Asn, CBG Lyon) in a Brazilian kindred: 756
Burger, H.G. *see* Tong, S.
Burrin, J.M. *see* Isidori, A.M.
Cannavò, S., Venturino, M., Curtò, L., de Menis, E., D'Arrigo, C., Tita, P., Billeci, D. & Trimarchi, F. Clinical presentation and outcome of pituitary adenomas in teenagers: 519
Caporaso, N. *see* Sorvillo, F.
Carbone, A. *see* Sorvillo, F.
Carbunaru, G. *see* Pang, S.
Cardoni, O. *see* Vaccaro, O.
Carella, C. *see* Sorvillo, F.
Carnevale, V. *see* Scillitani, A.

© 2003 Blackwell Science Ltd

Casamitjana, R. *see* Gómez, J.M.
Casanueva, F.F. *see* Broglio, F.
Casanueva, F.F. *see* Grottoli, S.
Casanueva, F.F. *see* van Dam, P.S.
Catalá, M. *see* Lucas, T.
Cavaco, B.M. *see* Pannett, A.A.J.
Cetani, F., Pardi, E., Borsari, S., Tonacchera, M., Morabito, E., Pinchera, A. & Marcocci, C. Two Italian kindreds with familial hypocalciuric hypercalcaemia caused by loss-of-function mutations in the calcium-sensing receptor (CaR) gene: functional characterization of a novel CaR missense mutation: 199
Chang, Y.T. *see* Pang, S.
Charmandari, E. *see* Roche, E.F.
Chen, Y.-T. *see* Sheu, W.H.-H.
Chiodini, I. *see* Scillitani, A.
Chiu, C.-Y. *see* Su, C.-C.
Choong, C. *see* Jack, M.M.
Choong, C. *see* McLennan, K.
Choubtum, L. *see* Mahachoklertwattana, P.
Christ, E.R., Simpson, H.L., Breen, L., Sönksen, P.H., Russell-Jones, D.L. & Kohner, E.M. The effect of growth hormone (GH) replacement therapy in adult patients with type 1 diabetes mellitus and GH deficiency: 309
Christiansen, J.S. *see* Jørgensen, J.O.L.
Chuansumrit, A. *see* Mahachoklertwattana, P.
Cianci, M. *see* Pellegriti, G.
Cianferotti, L. *see* Pannett, A.A.J.
Ciccarelli, E. *see* Scillitani, A.
Cioffi, M. *see* Sorvillo, F.
Clayton, P.E. *see* Zaman, N.
Coebergh, J.W.W. *see* Dragoiescu, C.
Colao, A. *see* Di Somma, C.
Colao, A. *see* Scillitani, A.
Colao, A., Marzullo, P., Cuocolo, A., Spinelli, L., Pivonello, R., Bonaduce, D., Salvatore, M. & Lombardi, G. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide: 169
Coleman, L. *see* McDonnell, C.M.
Colosimo, C. *see* Corsello, S.M.
Cooper, A. *see* Proudler, A.J.
Copeland, K.C. *see* Pang, S.
Cordido, F. *see* van Dam, P.S.
Corneli, G. *see* Grottoli, S.
Corsello, S.M., Ubertini, G., Altomare, M., Lovicu, R.M., Migneco, M.G., Rota, C.A. & Colosimo, C. Giant prolactinomas in men: efficacy of cabergoline treatment: 662
Cotterill, A. *see* McLennan, K.
Cotterill, A.M. *see* Jack, M.M.
Cowley, D. *see* McLennan, K.
Cowley, D.M. *see* Jack, M.M.
Crofton, P.M., Thomson, A.B., Evans, A.E.M., Groome, N.P., Bath, L.E., Kelnar, C.J.H. & Wallace, W.H.B. Is inhibin B a potential marker of gonadotoxicity in prepubertal children treated for cancer?: 296
Crook, D. *see* von Eckardstein, A.
Cruickshank, K. *see* Heald, A.H.
Cuocolo, A. *see* Colao, A.
Cuomo, V. *see* Vaccaro, O.
Curtò, L. *see* Cannavò, S.
Czernichow, P. *see* Zenaty, D.
D'Arrigo, C. *see* Cannavò, S.
D'Alva, C.B. *see* Boson, W.L.
Dalais, F.S., Ebeling, P.R., Kotsopoulos, D., McGrath, B.P. & Teede, H.J. The effects of soy protein containing isoflavones on lipids and indices of bone resorption in postmenopausal women: 704
van Dam, P.S., Dieguez, C., Cordido, F., de Vries, W.R., Veldhuyzen, B.F.E., van Thiel, E., Casanueva, F.F. & Koppeschaar, H.P.F. Diagnosis of growth hormone deficiency after pituitary surgery: the combined acipimox/GH-releasing hormone test: 156
Dane-Stewart, C.A., Watts, G.F., Barrett, P.H.R., Stuckey, B.G.A., Mamo, J.C.L., Martins, I.J. & Redgrave, T.G. Chylomicron remnant metabolism studied with a new breath test in postmenopausal women with and without type 2 diabetes mellitus: 415
Dattani, M.T. *see* Roche, E.F.
Davis, S.R. *see* Davison, S.
Davison, S. & Davis, S.R. Hormone replacement therapy: current controversies: 249
Dedecjus, M., Masson, D., Gautier, T., de Barros, J.-P.P., Gambert, P., Lewinski, A., Adamczewski, Z., Moulin, P. & Lagrost, L. Low cholesteryl ester transfer protein (CETP) concentration but normal CETP activity in serum from patients with short-term hypothyroidism Lack of relationship to lipoprotein abnormalities: 581
Deghenghi, R. *see* Broglio, F.
Dekker, F.W. *see* Terwee, C.B.
Delporte, M.L., Brichard, S.M., Hermans, M.P., Beguin, C. & Lambert, M. Hyperadiponectinaemia in anorexia nervosa: 22
Delvin, E. *see* Theodoropoulos, C.
Demers, C. *see* Theodoropoulos, C.
Demers, L.M. & Spencer, C.A. Laboratory Medicine Practice Guidelines: Laboratory Support for the Diagnosis and Monitoring of Thyroid Disease: 138
Di Somma, C., Pivonello, R., Loche, S., Faggiano, A., Klain, M., Salvatore, M., Lombardi, G. & Colao, A. Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study: 302
Diamant, M. *see* Pluijmen, M.J.H.M.
Dickinson, A.J. *see* Vaidya, B.
Dieguez, C. *see* Broglio, F.
Dieguez, C. *see* Grottoli, S.

Dieguez, C. *see* van Dam, P.S.
Dieplinger, H. *see* von Eckardstein, A.
Dietzmann, K. *see* Kanakis, D.
Diver, M.J., Imtiaz, K.E., Ahmad, A.M., Vora, J.P. & Fraser, W.D. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men: 710
Divine, G.W. *see* Rao, D.S.
Donaldson, M.D.C. *see* Kelly, B.P.
Donaubauer, J., Kiess, W., Kratzsch, J., Nowak, T., Steinkamp, H., Willgerodt, H. & Keller, E. Re-assessment of growth hormone secretion in young adult patients with childhood-onset growth hormone deficiency: 456
Dragoiescu, C., Hoekstra, O.S., Kuik, D.J., Lips, P., Plaizier, M.A.B.D., Rodrigus, P.T.R., Huijsmans, D.A.K.C.J.M., Ribot, J.G., Kuijpens, J., Coebergh, J.W.W. & Teule, G.J.J. Feasibility of a randomized trial on adjuvant radio-iodine therapy in differentiated thyroid cancer: 451
Dunger, D.B. *see* Ibáñez, L.
Ebeling, P.R. *see* Dalais, F.S.
von Eckardstein, A., Crook, D., Elbers, J., Ragoobir, J., Ezeh, B., Helmond, F., Miller, N., Dieplinger, H., Bennink, H.C. & Assmann, G. Tibolone lowers high density lipoprotein cholesterol by increasing hepatic lipase activity but does not impair cholesterol efflux: 49
Elbers, J. *see* von Eckardstein, A.
Elbers, J.M.H., Giltay, E.J., Teerlink, T., Scheffer, P.G., Asscheman, H., Seidell, J.C. & Gooren, L.J.G. Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects: 562
Eustatia-Rutten, C. *see* Pluijmen, M.J.H.M.
Evans, A.E.M. *see* Crofton, P.M.
Ezeh, B. *see* von Eckardstein, A.
Fabbri, A. *see* Aversa, A.
Faggiano, A. *see* Di Somma, C.
Fahie-Wilson, M.N. & Ahlquist, J.A. Hyperprolactinaemia due to macroprolactins: some progress but still a problem: 683
Faix, J.D. *see* Mitchell, M.L.
Fall, C.H.D. *see* Ward, A.M.V.
Faria, D. *see* Boson, W.L.
Feldt-Rasmussen, U. *see* Mersebach, H.
Ferreira, H.G. *see* Prazeres, S.
Flinter, F. *see* Pannett, A.A.J.
Forbes, S.A. *see* Pannett, A.A.J.
Franklyn, J.A. *see* McCabe, C.J.
Fraser, W.D. *see* Diver, M.J.
Fraser, W.D. *see* White, H.D.
Friedman, E. *see* Boson, W.L.
Frölich, M. *see* Biermasz, N.R.
Frystyk, J., Nyholm, B., Skjærbæk, C., Baxter, R.C., Schmitz, O. & Ørskov, H. The circulating IGF system and its relationship with 24-h glucose regulation and insulin sensitivity in healthy subjects: 777
Fujiwara, M. *see* Kammori, M.
Fukao, A., Takamatsu, J., Murakami, Y., Sakane, S., Miyauchi, A., Kuma, K., Hayashi, S. & Hanafusa, T. The relationship of psychological factors to the prognosis of hyperthyroidism in antithyroid drug-treated patients with Graves' disease: 550
Fukata, S. *see* Ito, M.
Fusilli, S. *see* Scillitani, A.
Gad, Y.Z. *see* Mazen, I.
Gaeta, G.B. *see* Sorvillo, F.
Gaia, D. *see* Scillitani, A.
Gambert, P. *see* Dedecjus, M.
Garel, C. *see* Zenaty, D.
Gascon-Barré, M. *see* Theodoropoulos, C.
Gasperi, M. *see* Scillitani, A.
Gauna, C. *see* Grottoli, S.
Gautier, T. *see* Dedecjus, M.
Gessl, A. *see* Raber, W.
Ghiggi, M.R. *see* Scillitani, A.
Ghigo, E. *see* Broglio, F.
Ghigo, E. *see* Grottoli, S.
Gibney, J. *see* McMillan, C.V.
Gibson, J.M. *see* Heald, A.H.
Gill, M.S. *see* Zaman, N.
Giltay, E.J. *see* Elbers, J.M.H.
Gittoes, N.J.L. *see* McCabe, C.J.
Gómez, J.M., Maravall, F.J., Gómez, N., Navarro, M.A., Casamitjana, R. & Soler, J. Interactions between serum leptin, the insulin-like growth factor-I system, and sex, age, anthropometric and body composition variables in a healthy population randomly selected: 213
Goldman, M.B. *see* Sowers, M.
Goldstone, A.P., Unmehopa, U.A. & Swaab, D.F. Hypothalamic growth hormone-releasing hormone (GHRH) cell number is increased in human illness, but is not reduced in Prader–Willi syndrome or obesity: 743
Gómez, N. *see* Gómez, J.M.
Gooren, L.J.G. *see* Elbers, J.M.H.
Goslings, B.M. *see* Pluijmen, M.J.H.M.
Gottero, C. *see* Broglio, F.
Greenman, Y., Ouaknine, G., Veshchev, I., Reider-Groswasser, I.I., Segev, Y. & Stern, N. Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth: 763
Greer, R.M. *see* Jack, M.M.
Groome, N.P. *see* Crofton, P.M.
Grottoli, S., Gauna, C., Tassone, F., Aimaretti, G., Corneli, G., Wu, Z., Strasburger, C.J., Dieguez, C., Casanueva, F.F., Ghigo, E. & Maccario, M. Both fasting-induced leptin reduction and GH increase are blunted in Cushing's syndrome and in simple obesity: 220
Guzder, R. *see* White, H.D.
Haddow, J.E. *see* Mitchell, M.L.

Hadjidakis, D., Tsagarakis, S., Roboti, C., Sfakianakis, M., Iconomidou, V., Raptis, S.A. & Thalassinos, N. Does subclinical hypercortisolism adversely affect the bone mineral density of patients with adrenal incidentalomas?: 72
Hafez, M. *see* Mazen, I.
Hagen, C. *see* Svensson, J.
Haider, A. *see* Pang, S.
Hall, C.M. *see* Zaman, N.
Hana, V. *see* Silha, J.V.
Hanafusa, T. *see* Fukao, A.
Hanafusa, T. *see* Ito, M.
Hansen, T.K. *see* Svensson, J.
Harding, B. *see* Pannett, A.A.J.
Hardy, J. *see* Beauregard, C.
Harlow, S.D. *see* Sowers, M.
Hawkins, F. *see* Jódar, E.
Hayashi, S. *see* Fukao, A.
Heald, A.H., Ivison, F., Anderson, S.G., Cruickshank, K., Laing, I. & Gibson, J.M. Significant ethnic variation in total and free testosterone concentration: 262
Heaney, A.P. *see* McCabe, C.J.
Heisterkamp, S.H. *see* Terwee, C.B.
Helmond, F. *see* von Eckardstein, A.
Herington, A.C. *see* Jack, M.M.
Hermans, M.P. *see* Delporte, M.L.
Hidaka, Y. *see* Tada, H.
Hilding, A. *see* Höybye, C.
Hindmarsh, P.C. *see* Mundy, H.R.
Hindmarsh, P.C. *see* Roche, E.F.
Hoekstra, O.S. *see* Dragoiescu, C.
Holst, J.J. *see* Mersebach, H.
Hong, S.J. *see* Koh, J.-M.
Howard, N. *see* McLennan, K.
Höybye, C., Hilding, A., Jacobsson, H. & Thorén, M. Growth hormone treatment improves body composition in adults with Prader–Willi syndrome: 653
Hughes, I.A. *see* Wallace, A.M.
Huijsmans, D.A.K.C.J.M. *see* Dragoiescu, C.
Hussain, S. *see* McCabe, C.J.
Ian Mason, J. *see* Pang, S.
Ibáñez, L., Ong, K., de Zegher, F., Marcos, M.V., del Rio, L. & Dunger, D.B. Fat distribution in non-obese girls with and without precocious pubarche: central adiposity related to insulinaemia and androgenaemia from prepuberty to postmenarche: 372
Iconomidou, V. *see* Hadjidakis, D.
Iitsuka, Y. *see* Sakamoto, R.
Ilondo, M.M. *see* Svensson, J.
Imrie, H. *see* Vaidya, B.
Imtiaz, K.E. *see* Diver, M.J.
Ishikawa, S.-E. & Schrier, R.W. Pathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretion: 1
Isidori, A.M. *see* Aversa, A.
Isidori, A.M., Kaltsas, G.A., Perry, L., Burrin, J.M., Besser, G.M. & Monson, J.P. The effect of growth hormone replacement therapy on adrenal androgen secretion in adult onset hypopituitarism: 601
Itakura, M. *see* Yamasaki, H.
Ito, K. *see* Utsunomiya, H.
Ito, M., Takamatsu, J., Matsuo, T., Kameoka, K., Kubota, S., Fukata, S., Tamai, H., Miyauchi, A., Kuma, K. & Hanafusa, T. Serum concentrations of remnant-like particles in hypothyroid patients before and after thyroxine replacement: 621
Ivison, F. *see* Heald, A.H.
Izumi, Y. *see* Tada, H.
Izumiyama-Shimomura, N. *see* Kammori, M.
Jack, M.M., Greer, R.M., Thomsett, M.J., Walker, R.M., Bell, J.R., Choong, C., Cowley, D.M., Herington, A.C. & Cotterill, A.M. The outcome in Australian children with hyperinsulinism of infancy: early extensive surgery in severe cases lowers risk of diabetes: 355
Jacobsen, G. *see* Rao, D.S.
Jacobsson, H. *see* Höybye, C.
Jap, T.-S. *see* Su, C.-C.
Jara, A. *see* Jódar, E.
Jeske, Y. *see* McLennan, K.
Jezkova, J. *see* Silha, J.V.
Jódar, E., Valdepeñas, M.P.R., Martinez, G., Jara, A. & Hawkins, F. Long-term follow-up of bone mineral density in Addison's disease: 617
Jones, J. *see* Zaman, N.
Jones, T. *see* McLennan, K.
de Jong, F.H. *see* de Ronde, W.
Jørgensen, J.O.L. & Christiansen, J.S. Testing for growth hormone deficiency in adults – how to respond?: 18
Jørgensen, T. *see* Pedersen, I.B.
Kaku, K. *see* Sakamoto, R.
Kaltsas, G.A. *see* Isidori, A.M.
Kameoka, K. *see* Ito, M.
Kaminishi, M. *see* Kammori, M.
Kammori, M., Nakamura, K.-I., Ogawa, T., Mafune, K.-I., Tatutomi, Y., Obara, T., Onoda, N., Fujiwara, M., Izumiyama-Shimomura, N., Mori, M., Kaminishi, M. & Takubo, K. Demonstration of human telomerase reverse transcriptase (hTERT) in human parathyroid tumours by *in situ* hybridization with a new oligonucleotide probe: 43
Kanakis, D., Kirches, E., Mawrin, C. & Dietzmann, K. Promoter mutations are no major cause of PTTG overexpression in pituitary adenomas: 151
Kann, P. *see* Svensson, J.
Kanumakala, S. *see* Zacharin, M.R.
Keller, E. *see* Donaubauer, J.
Kelly, B.P., Paterson, W.F. & Donaldson, M.D.C. Final height outcome and value of height prediction in boys with constitutional delay in growth and adolescence treated with intramuscular testosterone 125 mg per month for 3 months: 267

Kelnar, C.J.H. *see* Crofton, P.M.
Kendall-Taylor, P. Guidelines for the management of thyroid cancer: 400
Kendall-Taylor, P. *see* Vaidya, B.
Kennedy, A.M. *see* Pannett, A.A.J.
Khaira, J.S. *see* McCabe, C.J.
Kiess, W. *see* Donaubauer, J.
Kim, E.S. *see* Koh, J.-M.
Kim, W.B. *see* Koh, J.-M.
Kinniburgh, D. *see* Brady, B.M.
Kirches, E. *see* Kanakis, D.
Klain, M. *see* Di Somma, C.
Klein, R.Z. *see* Mitchell, M.L.
Knudsen, N. *see* Pedersen, I.B.
Koh, J.-M., Kim, E.S., Ryu, J.S., Hong, S.J., Kim, W.B. & Shong, Y.K. Effects of therapeutic doses of ^{131}I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative ^{131}I whole-body scan: comparative study: 421
Kohner, E.M. *see* Christ, E.R.
Konno, R. *see* Utsunomiya, H.
Kooh, S.W. *see* Mäkitie, O.
Koppeschaar, H.P.F. *see* van Dam, P.S.
Korbonits, M. *see* Svensson, J.
Kotsopoulos, D. *see* Dalais, F.S.
Kratzsch, J. *see* Donaubauer, J.
Krsek, M. *see* Silha, J.V.
Kubota, S. *see* Ito, M.
Kuijpens, J. *see* Dragoiescu, C.
Kuik, D.J. *see* Dragoiescu, C.
Kuma, K. *see* Fukao, A.
Kuma, K. *see* Ito, M.
Kumaran, K. *see* Ward, A.M.V.
Lagrost, L. *see* Dedecjus, M.
Laing, I. *see* Heald, A.H.
Lambert, M. *see* Delporte, M.L.
Laurberg, P. *see* Pedersen, I.B.
Laurenzi, M. *see* Vaccaro, O.
Lee, P.J. *see* Mundy, H.R.
Lee, W.-J. *see* Sheu, W.H.-H.
van Leeuwen, J.P.T.M. *see* de Ronde, W.
Léger, J. *see* Zenaty, D.
van der Lely, A.J. *see* Broglio, F.
Lenzi, A. *see* Aversa, A.
Leonard, J.V. *see* Mundy, H.R.
Levy, A. Hazards of dynamic testing of pituitary function: 543
Lewinski, A. *see* Dedecjus, M.
Limoni, C. *see* Zenaty, D.
Lin, L.-Y. *see* Sheu, W.H.-H.
Lin, S.Y., Wang, Y.Y. & Sheu, W.H.-H. Preoperative plasma concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 are associated with stage progression in papillary thyroid cancer: 513
Lips, P. *see* Dragoiescu, C.
Lissett, C.A. & Shalet, S.M. The insulin-like growth factor-I generation test: peripheral responsiveness to growth hormone is not decreased with ageing: 238
Liuzzi, A. *see* Scillitani, A.
Loche, S. *see* Di Somma, C.
Lombardi, G. *see* Colao, A.
Lombardi, G. *see* Di Somma, C.
Lovicu, R.M. *see* Corsello, S.M.
Luborsky, J. *see* Sowers, M.
Lucas, T., Astorga, R. & Catalá, M. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage: 471
Lumbroso, S. *see* Mazen, I.
Lutfallah, C. *see* Pang, S.
Maccario, M. *see* Grottoli, S.
Mafune, K.-I. *see* Kammori, M.
Mahachoklertwattana, P., Chuansumrit, A., Sirisriro, R., Choubtum, L., Sriphrapradang, A. & Rajatanavin, R. Bone mineral density, biochemical and hormonal profiles in suboptimally treated children and adolescents with β-thalassaemia disease: 273
Maidment, C.G.H. *see* Pannett, A.A.J.
Mäkitie, O., Kooh, S.W. & Sochett, E. Prolonged high-dose phosphate treatment: a risk factor for tertiary hyperparathyroidism in X-linked hypophosphatemic rickets: 163
Mamo, J.C.L. *see* Dane-Stewart, C.A.
Mancini, M. *see* Vaccaro, O.
Maravall, F.J. *see* Gómez, J.M.
de Marco L. *see* Boson, W.L.
Marcocci, C. *see* Cetani, F.
Marcos, M.V. *see* Ibáñez, L.
Marek, J. *see* Silha, J.V.
Marozzi, P. *see* Pellegriti, G.
Martin, F.C. *see* Weissberger, A.J.
Martinez, G. *see* Jódar, E.
Martins, I.J. *see* Dane-Stewart, C.A.
Marzullo, P. *see* Colao, A.
Masson, D. *see* Dedecjus, M.
Masuda, K. *see* Sakamoto, R.
Matsuo, T. *see* Ito, M.
Matthews, D.R. *see* Mundy, H.R.
Mawrin, C. *see* Kanakis, D.
Mazen, I., Gad, Y.Z., Hafez, M., Sultan, C. & Lumbroso, S. Molecular analysis of 5α-reductase type 2 gene in eight unrelated egyptian children with suspected 5α-reductase deficiency: prevalence of the G34R mutation: 627
Mazziotti, G. *see* Sorvillo, F.
McCabe, C.J. & Heaney, A.P. Pituitary tumour transforming gene in endocrine cancer: 673
McCabe, C.J., Khaira, J.S., Boelaert, K., Heaney, A.P., Tannahill, L.A., Hussain, S., Mitchell, R., Olliff, J., Sheppard, M.C., Franklyn J.A. & Gittoes, N.J.L. Expression of pituitary tumour transforming gene

(PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumour behaviour: 141
McDonnell, C.M., Coleman, L. & Zacharin, M.R. A 3-year prospective study to assess uterine growth in girls with Turner's syndrome by pelvic ultrasound: 446
McGrath, B.P. *see* Dalais, F.S.
McLennan, K., Jeske, Y., Cotterill, A., Cowley, D., Penfold, J., Jones, T., Howard, N., Thomsett, M. & Choong, C. Combined pituitary hormone deficiency in Australian children: clinical and genetic correlates: 785
McMillan, C.V., Bradley, C., Gibney, J., Russell-Jones, D.L. & Sönksen, P.H. Evaluation of two health status measures in adults with growth hormone deficiency: 436
Ménard, D. *see* Theodoropoulos, C.
de Menis, E. *see* Cannavò, S.
Mersebach, H., Svendsen, O.L., Holst, J.J., Astrup, A. & Feldt-Rasmussen, U. Comparisons of leptin, incretins and body composition in obese and lean patients with hypopituitarism and healthy individuals: 65
Meter, R.A. *see* Mitchell, M.L.
Migneco, M.G. *see* Corsello, S.M.
Miller, N. *see* von Eckardstein, A.
Minetto, M. *see* Reimondo, G.
Mitchell, M.L., Klein, R.Z., Sargent, J.D., Meter, R.A., Haddow, J.E., Waisbren, S.E. & Faix, J.D. Iodine sufficiency and measurements of thyroid function in maternal hypothyroidism: 612
Mitchell, R. *see* McCabe, C.J.
Miyauchi, A. *see* Fukao, A.
Miyauchi, A. *see* Ito, M.
Mizusawa, N. *see* Yamasaki, H.
Mizuta, I. *see* Tada, H.
Monson, J.P. *see* Isidori, A.M.
Monson, J.P. *see* Svensson, J.
Morabito, E. *see* Cetani, F.
Mori, M. *see* Kammori, M.
Morisco, F. *see* Sorvillo, F.
Moriya, T. *see* Utsunomiya, H.
Mossetti, G. *see* Palomba, S.
Moulin, P. *see* Dedecjus, M.
Mundy, H.R., Hindmarsh, P.C., Matthews, D.R., Leonard, J.V. & Lee, P.J. The regulation of growth in glycogen storage disease type 1: 332
Murakami, Y. *see* Fukao, A.
Murphy, L.J. *see* Silha, J.V.
Naderi, A.R. & Safarinejad, M.R. Endocrine profiles and semen quality in spinal cord injured men: 177
Nagahiro, S. *see* Yamasaki, H.
Nakamura, K.-I. *see* Kammori, M.
Nappi, C. *see* Palomba, S.
Navarro, M.A. *see* Gómez, J.M.
Nowak, T. *see* Donaubauer, J.
Nowotny, P. *see* Raber, W.
Numis, F.G. *see* Palomba, S.
Nunziata, V. *see* Palomba, S.
Nyholm, B. *see* Frystyk, J.
Oakes, E.J.C. *see* Vaidya, B.
Obara, T. *see* Kammori, M.
van den Oever, N.C. *see* Biermasz, N.R.
Ogawa, T. *see* Kammori, M.
Okamura, K. *see* Utsunomiya, H.
Olliff, J. *see* McCabe, C.J.
Ong, K. *see* Ibáñez, L.
Onoda, N. *see* Kammori, M.
Oppizzi, G. *see* Scillitani, A.
Ørskov, H. *see* Frystyk, J.
Osada, H. *see* Sakamoto, R.
Ouaknine, G. *see* Greenman, Y
Ovesen, L. *see* Pedersen, I.B.
Paccotti, P. *see* Reimondo, G.
Palomba, S., Numis, F.G., Mossetti, G., Rendina, D., Vuotto, P., Russo, T., Zullo, F., Nappi, C. & Nunziata, V. Effectiveness of alendronate treatment in postmenopausal women with osteoporosis: relationship with Bsml vitamin D receptor genotypes: 365
Panarelli, W. *see* Vaccaro, O.
Pang, S., Carbunaru, G., Haider, A., Copeland, K.C., Chang, Y.T., Lutfallah, C. & Ian Mason, J. Carriers for type II 3β-hydroxysteroid dehydrogenase (HSD3B2) deficiency can only be identified by *HSD3B2* genotype study and not by hormone test: 323
Pannett, A.A.J., Kennedy, A.M., Turner, J.J.O., Forbes, S.A., Cavaco, B.M., Bassett, J.H.D., Cianferotti, L., Harding, B., Shine, B., Flinter, F., Maidment, C.G.H., Trembath, R. & Thakker, R.V. Multiple endocrine neoplasia type 1 (MEN1) germline mutations in familial isolated primary hyperparathy-roidism: 639
Papanicolaou, D.A. *see* Rotman-Pikielny, P.
Pardi, E. *see* Cetani, F.
Parfitt, A.M. *see* Rao, D.S.
Paterson, W.F. *see* Kelly, B.P.
Patronas, N. *see* Rotman-Pikielny, P.
Pearce, S.H.S. *see* Vaidya, B.
Pedersen, I.B., Knudsen, N., Jørgensen, T., Perrild, H., Ovesen, L. & Laurberg, P. Thyroid peroxidase and thyroglobulin autoantibodies in a large survey of populations with mild and moderate iodine deficiency: 36
Pellegriti, G., Scollo, C., Regalbuto, C., Attard, M., Marozzi, P., Vermiglio, F., Violi, M.A., Cianci, M., Vigneri, R., Pezzino, V. & Squatrito, S. The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels: 556
Penfold, J. *see* McLennan, K.
Perdue, C. *see* Sowers, M.
Pereira Arias, A.M. *see* Biermasz, N.R.
Perrild, H. *see* Pedersen, I.B.
Perros, P. *see* Vaidya, B.
Perry, L. *see* Isidori, A.M.
Pezzino, V. *see* Pellegriti, G.
Phillips, D.I.W. *see* Ward, A.M.V.

Pinchera, A. *see* Cetani, F.
Pivonello, R. *see* Colao, A.
Pivonello, R. *see* Di Somma, C.
Plaizier, M.A.B.D. *see* Dragoiescu, C.
Pluijmen, M.J.H.M., Eustatia-Rutten, C., Goslings, B.M., Stokkel, M.P., Arias, A.M.P., Diamant, M., Romijn, J.A. & Smit, J.W.A. Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma: 428
Pols, H.A.P. *see* de Ronde, W.
Prazeres, S., Santos, M.A., Ferreira, H.G. & Sobrinho, L.G. A practical method for the detection of macroprolactinaemia using ultrafiltration: 686
Prodam, F. *see* Broglio, F.
Proudler, A.J., Cooper, A., Whitehead, M. & Stevenson, J.C. Effects of oestrogen-only and oestrogen–progestogen replacement therapy upon circulating angiotensin I-converting enzyme activity in postmenopausal women: 30
Prummel, M.F. *see* Terwee, C.B.
Prummel, M.F. *see* Wakelkamp, I.M.M.J.
Pua, J. *see* Zacharin, M.R.
Raber, W., Gessl, A., Nowotny, P. & Vierhapper, H. Hyperprolactinaemia in hypothyroidism: clinical significance and impact of TSH normalization: 185
Ragoobir, J. *see* von Eckardstein, A.
Rajatanavin, R. *see* Mahachoklertwattana, P.
Rao, D.S., Wallace, E.A., Antonelli, R.F., Talpos, G.B., Ansari, M.R., Jacobsen, G., Divine, G.W. & Parfitt, A.M. Forearm bone density in primary hyperparathyroidism: long-term follow-up with and without parathyroidectomy: 348
Raptis, S.A. *see* Hadjidakis, D.
Redgrave, T.G. *see* Dane-Stewart, C.A.
Regalbuto, C. *see* Pellegriti, G.
Reider-Groswasser, I.I. *see* Greenman, Y.
Reimondo, G., Paccotti, P., Minetto, M., Termine, A., Stura, G., Bergui, M., Angeli, A. & Terzolo, M. The corticotrophin-releasing hormone test is the most reliable noninvasive method to differentiate pituitary from ectopic ACTH secretion in Cushing's syndrome: 718
Reincke, M. *see* Svensson, J.
Rendina, D. *see* Palomba, S.
Ribot, J.G. *see* Dragoiescu, C.
Riccardi, G. *see* Vaccaro, O.
del Rio, L. *see* Ibáñez, L.
Roboti, C. *see* Hadjidakis, D.
Roche, E.F., Charmandari, E., Dattani, M.T. & Hindmarsh, P.C. Blood pressure in children and adolescents with congenital adrenal hyperplasia (21-hydroxylase deficiency): a preliminary report: 589
Rodrigus, P.T.R. *see* Dragoiescu, C.
Roelfsema, F. *see* Biermasz, N.R.
Rogol, A.D., Blethen, S.L., Sy, J.P. & Veldhuis, J.D. Do growth hormone (GH) serial sampling, insulin-like growth factor-I (IGF-I) or auxological measurements have an advantage over GH stimulation testing in predicting the linear growth response to GH therapy?: 229
Romijn, J.A. *see* Biermasz, N.R.
Romijn, J.A. *see* Pluijmen, M.J.H.M.
de Ronde, W., Pols, H.A.P., van Leeuwen, J.P.T.M. & de Jong, F.H. The importance of oestrogens in males: 529
Rota, C.A. *see* Corsello, S.M.
Rotman-Pikielny, P., Patronas, N. & Papanicolaou, D.A. Pituitary apoplexy induced by corticotrophin-releasing hormone in a patient with Cushing's disease: 545
Rotondi, M. *see* Sorvillo, F.
Russell-Jones, D.L. *see* Christ, E.R.
Russell-Jones, D.L. *see* McMillan, C.V.
Russo, T. *see* Palomba, S.
Ryu, J.S. *see* Koh, J.-M.
Safarinejad, M.R. *see* Naderi, A.R.
Sakamoto, R., Osada, H., Iitsuka, Y., Masuda, K., Kaku, K., Seki, K. & Sekiya, S. Profile of neurokinin B concentrations in maternal and cord blood in normal pregnancy: 597
Sakane, S. *see* Fukao, A.
Salvatore, M. *see* Colao, A.
Salvatore, M. *see* Di Somma, C.
Sano, T. *see* Yamasaki, H.
Santos, M.A. *see* Prazeres, S.
Sargent, J.D. *see* Mitchell, M.L.
Sarubi, J.C. *see* Boson, W.L.
Sasano, H. *see* Utsunomiya, H.
Sato, S. *see* Utsunomiya, H.
Savine, R. *see* Svensson, J.
Scheffer, P.G. *see* Elbers, J.M.H.
Schmitz, O. *see* Frystyk, J.
Schrier, R.W. *see* Ishikawa, S.-E.
Scillitani, A., Battista, C., Chiodini, I., Carnevale, V., Fusilli, S., Ciccarelli, E., Terzolo, M., Oppizzi, G., Arosio, M., Gasperi, M., Arnaldi, G., Colao, A., Baldelli, R., Ghiggi, M.R., Gaia, D., Somma, C.D., Trischitta, V. & Liuzzi, A. Bone mineral density in acromegaly: the effect of gender, disease activity and gonadal status: 725
Scollo, C. *see* Pellegriti, G.
Segev, Y. *see* Greenman, Y.
Seidell, J.C. *see* Elbers, J.M.H.
Seki, K. *see* Sakamoto, R.
Sekiya, S. *see* Sakamoto, R.
Serri, O. *see* Beauregard, C.
Sfakianakis, M. *see* Hadjidakis, D.
Shalet, S.M. *see* Lissett, C.A.
Sheppard, M.C. Primary medical therapy for acromegaly: 387
Sheppard, M.C. *see* McCabe, C.J.
Sheu, W.H.-H. *see* Lin, S.Y.
Sheu, W.H.-H., Chen, Y.-T., Lee, W.-J., Wang, C.-W. & Lin, L.-Y. A relationship between serum ferritin and the insulin resistance syndrome is present in non-diabetic women but not in non-diabetic men: 380
Shine, B. *see* Pannett, A.A.J.
Shong, Y.K. *see* Koh, J.-M.

Silha, J.V., Krsek, M., Hana, V., Marek, J., Jezkova, J., Weiss, V. & Murphy, L.J. Perturbations in adiponectin, leptin and resistin levels in acromegaly: lack of correlation with insulin resistance: 736
Simpson, H.L. *see* Christ, E.R.
Sirisriro, R. *see* Mahachoklertwattana, P.
Skjærbæk, C. *see* Frystyk, J.
Smit, J.W.A. *see* Biermasz, N.R.
Smit, J.W.A. *see* Pluijmen, M.J.H.M.
Smith, M.A. *see* Weissberger, A.J.
Sobrinho, L.G. *see* Prazeres, S.
Sochett, E. *see* Mäkitie, O.
Soler, J. *see* Gómez, J.M.
Somma, C.D. *see* Scillitani, A.
Sönksen, P.H. *see* Christ, E.R.
Sönksen, P.H. *see* McMillan, C.V.
Sönksen, P.H. *see* Weissberger, A.J.
Sorvillo, F., Mazziotti, G., Carbone, A., Morisco, F., Cioffi, M., Rotondi, M., Stornaiuolo, G., Amato, G., Gaeta, G.B., Caporaso, N. & Carella, C. Increased serum reverse triiodothyronine levels at diagnosis of hepatocellular carcinoma in patients with compensated HCV-related liver cirrhosis: 207
Sowers, M., Luborsky, J., Perdue, C., Araujo, K.L.B., Goldman, M.B. & Harlow, S.D. Thyroid stimulating hormone (TSH) concentrations and menopausal status in women at the mid-life: SWAN: 340
Spencer, C.A. *see* Demers, L.M.
Spera, G. *see* Aversa, A.
Spinelli, L. *see* Colao, A.
Squatrito, S. *see* Pellegriti, G.
Sriphrapradang, A. *see* Mahachoklertwattana, P.
Stein, C.E. *see* Ward, A.M.V.
Steinkamp, H. *see* Donaubauer, J.
Stern, N. *see* Greenman, Y.
Stevenson, J.C. *see* Proudler, A.J.
Stokkel, M.P. *see* Pluijmen, M.J.H.M.
Stornaiuolo, G. *see* Sorvillo, F.
Strasburger, C.J. *see* Grottoli, S.
Stuckey, B.G.A. *see* Dane-Stewart, C.A.
Stura, G. *see* Reimondo, G.
Sturgess, I. *see* Weissberger, A.J.
Su, C.-C., Wu, Y.-C., Chiu, C.-Y., Won, J.G.-S. & Jap, T.-S. Two novel mutations in the gene encoding thyroxine-binding globulin (TBG) as a cause of complete TBG deficiency in Taiwan: 409
Sultan, C. *see* Mazen, I.
Suzuki, T. *see* Utsunomiya, H.
Svendsen, O.L. *see* Mersebach, H.
Svensson, J., Monson, J.P., Vetter, T., Hansen, T.K., Savine, R., Kann, P., Bex, M., Reincke, M., Hagen, C., Beckers, A., Ilondo, M.M., Zdravkovic, M., Bengtsson, B.-Å. & Korbonits, M. Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency: 572
Swaab, D.F. *see* Goldstone, A.P.
Sy, J.P. *see* Rogol, A.D.
Syddall, H.E. *see* Ward, A.M.V.
Tada, H., Mizuta, I., Takano, T., Tatsumi, K.-I., Izumi, Y., Hidaka, Y. & Amino, N. Blocking-type anti-TSH receptor antibodies and relation to responsiveness to antithyroid drug therapy and remission in Graves' disease: 403
Takamatsu, J. *see* Fukao, A.
Takamatsu, J. *see* Ito, M.
Takano, T. *see* Tada, H.
Takubo, K. *see* Kammori, M.
Talpos, G.B. *see* Rao, D.S.
Tamai, H. *see* Ito, M.
Tannahill, L.A. *see* McCabe, C.J.
Tassone, F. *see* Grottoli, S.
Tatsumi, K.-I. *see* Tada, H.
Tatutomi, Y. *see* Kammori, M.
Teede, H.J. *see* Dalais, F.S.
Teerlink, T. *see* Elbers, J.M.H.
Termine, A. *see* Reimondo, G.
Terwee, C.B., Dekker, F.W., Bonsel, G.J., Heisterkamp, S.H., Prummel, M.F., Baldeschi, L. & Wiersinga, W.M. Facial disfigurement: is it in the eye of the beholder? A study in patients with Graves' ophthalmopathy: 192
Terzolo, M. *see* Reimondo, G.
Terzolo, M. *see* Scillitani, A.
Teule, G.J.J. *see* Dragoiescu, C.
Thakker, R.V. *see* Pannett, A.A.J.
Thalassinos, N. *see* Hadjidakis, D.
Theodoropoulos, C., Demers, C., Delvin, E., Ménard, D. & Gascon-Barré, M. Calcitriol regulates the expression of the genes encoding the three key vitamin D_3 hydroxylases and the drug-metabolizing enzyme CYP3A4 in the human fetal intestine: 489
van Thiel, E. *see* van Dam, P.S.
Thomsett, M. *see* McLennan, K.
Thomsett, M.J. *see* Jack, M.M.
Thomson, A.B. *see* Crofton, P.M.
Thorén, M. *see* Höybye, C.
Thorner, M.O. Controversy: radiotherapy for acromegaly: 136
Tillmann, V. *see* Zaman, N.
Tita, P. *see* Cannavò, S.
Toft, A.D. *see* Beckett, G.J.
Tonacchera, M. *see* Cetani, F.
Tong, S., Wallace, E.M. & Burger, H.G. Inhibins and activins: clinical advances in reproductive medicine: 115
Trembath, R. *see* Pannett, A.A.J.
Trimarchi, F. *see* Cannavò, S.
Trischitta, V. *see* Scillitani, A.
Truong, U. *see* Beauregard, C.
Tsagarakis, S. *see* Hadjidakis, D.

Tucker, P. *see* Wallace, A.M.
Turner, H.E. *see* Bradley, K.J.
Turner, J.J.O. *see* Pannett, A.A.J.
Ubertini, G. *see* Corsello, S.M.
Unmehopa, U.A. *see* Goldstone, A.P.
Utsunomiya, H., Suzuki, T., Ito, K., Moriya, T., Konno, R., Sato, S., Yaegashi, N., Okamura, K. & Sasano, H. The correlation between the response to progestogen treatment and the expression of progesterone receptor B and 17β-hydroxysteroid dehydrogenase type 2 in human endometrial carcinoma: 696
Vaccaro, O., Cardoni, O., Cuomo, V., Panarelli, W., Laurenzi, M., Mancini, M., Riccardi, G. & Zanchetti, A. Relationship between plasma insulin and left ventricular mass in normotensive participants of the Gubbio Study: 316
Vaidya, B., Oakes, E.J.C., Imrie, H., Dickinson, A.J., Perros, P., Kendall-Taylor, P. & Pearce, S.H.S. CTLA4 gene and Graves' disease: association of Graves' disease with the CTLA4 exon 1 and intron 1 polymorphisms, but not with the promoter polymorphism: 732
Valdepeñas, M.P.R. *see* Jódar, E.
Veena, S.R. *see* Ward, A.M.V.
Veldhuis, J.D. *see* Rogol, A.D.
Veldhuyzen, B.F.E. *see* van Dam, P.S.
Venturino, M. *see* Cannavò, S.
Vermiglio, F. *see* Pellegriti, G.
Veshchev, I. *see* Greenman, Y
Vetter, T. *see* Svensson, J.
Vieira, J.G.H. *see* Brunner, E.
Vieira, T.C. *see* Brunner, E.
Vierhapper, H. *see* Raber, W.
Vigneri, R. *see* Pellegriti, G.
Violi, M.A. *see* Pellegriti, G.
Vora, J.P. *see* Diver, M.J.
Vora, J.P. *see* White, H.D.
de Vries, W.R. *see* van Dam, P.S.
Vuotto, P. *see* Palomba, S.
Waisbren, S.E. *see* Mitchell, M.L.
Wajchenberg, B. *see* Boson, W.L.
Wakelkamp, I.M.M.J., Bakker, O., Baldeschi, L., Wiersinga, W.M. & Prummel, M.F. TSH-R expression and cytokine profile in orbital tissue of active *vs.* inactive Graves' ophthalmopathy patients: 280
Walker, R.M. *see* Jack, M.M.
Wallace, A.M. *see* White, H.D.
Wallace, A.M., Tucker, P., Williams, D.M., Hughes, I.A. & Ahmed, S.F. Short-term effects of prednisolone and dexamethasone on circulating concentrations of leptin and sex hormone-binding globulin in children being treated for acute lymphoblastic leukaemia: 770
Wallace, E.A. *see* Rao, D.S.
Wallace, E.M. *see* Tong, S.
Wallace, W.H.B. *see* Crofton, P.M.
Wang, C.-W. *see* Sheu, W.H.-H.
Wang, Y.Y. *see* Lin, S.Y.
Ward, A.M.V., Fall, C.H.D., Stein, C.E., Kumaran, K., Veena, S.R., Wood, P.J., Syddall, H.E. & Phillips, D.I.W. Cortisol and the metabolic syndrome in South Asians: 500
Wass, J.A.H. Radiotherapy in acromegaly: a protagonists viewpoint: 128
Wass, J.A.H. *see* Bradley, K.J.
Watts, G.F. *see* Dane-Stewart, C.A.
Weiss, V. *see* Silha, J.V.
Weissberger, A.J., Anastasiadis, A.D., Sturgess, I., Martin, F.C., Smith, M.A. & Sönksen, P.H. Recombinant human growth hormone treatment in elderly patients undergoing elective total hip replacement: 99
Westwood, M. *see* Zaman, N.
Whatmore, A.J. *see* Zaman, N.
White, H.D., Ahmad, A.M., Guzder, R., Wallace, A.M., Fraser, W.D. & Vora, J.P. Gender variation in leptin circadian rhythm and pulsatility in adult growth hormone deficiency: effects of growth hormone replacement: 482
Whitehead, M. *see* Proudler, A.J.
Wiersinga, W.M. *see* Terwee, C.B.
Wiersinga, W.M. *see* Wakelkamp, I.M.M.J.
Willgerodt, H. *see* Donaubauer, J.
Williams, D.M. *see* Wallace, A.M.
Won, J.G.-S. *see* Su, C.-C.
Wood, P.J. *see* Ward, A.M.V.
Wu, Y.-C. *see* Su, C.-C.
Wu, Z. *see* Grottoli, S.
Yaegashi, N. *see* Utsunomiya, H.
Yamada, S. *see* Yamasaki, H.
Yamasaki, H., Mizusawa, N., Nagahiro, S., Yamada, S., Sano, T., Itakura, M. & Yoshimoto, K. GH-secreting pituitary adenomas infrequently contain inactivating mutations of PRKAR1A and LOH of 17q23–24: 464
Yoshimoto, K. *see* Yamasaki, H.
Zacharin, M.R. *see* McDonnell, C.M.
Zacharin, M.R., Pua, J. & Kanumakala, S. Bone mineral density outcomes following long-term treatment with subcutaneous testosterone pellet implants in male hypogonadism: 691
Zaman, N., Hall, C.M., Gill, M.S., Jones, J., Tillmann, V., Westwood, M., Whatmore, A.J. & Clayton, P.E. Leptin measurement in urine in children and its relationship to other growth peptides in serum and urine: 78
Zanchetti, A. *see* Vaccaro, O.
Zdravkovic, M. *see* Svensson, J.
de Zegher, F. *see* Ibáñez, L.
Zenaty, D., Garel, C., Limoni, C., Czernichow, P. & Léger, J. Presence of magnetic resonance imaging abnormalities of the hypothalamic–pituitary axis is a significant determinant of the first 3 years growth response to human growth hormone treatment in prepubertal children with nonacquired growth hormone deficiency: 647
Zullo, F. *see* Palomba, S.

Subject Index to Volume 58

ACE activity
HRT in postmenopausal women 30
Acetylcholine
influence on ghrelin in humans 92
Acipimox/GHRH test
diagnosis of GHD 156
Acne
cyproterone acetate treatment (Letter) 246
Acromegaly
6-weekly Sandostatin LAR injection 288
adiponectin, leptin and resistin levels in 736
BMD in 725
primary medical therapy (Review) 387
radiotherapy in (Commentary) 128, 132, 136
transsphenoidal adenomectomy outcome and mortality 86
treatment, and cardiomyopathy 169
ACTH
CRH test for secretion in Cushing's syndrome 718
immunopositive non-functioning pituitary adenomas 59
Activins
clinical advances in reproductive medicine (Review) 115
Addison's disease
BMD and long-term therapy 617
Adenomectomy, transsphenoidal
outcome and mortality for acromegaly 86
Adiponectin
in acromegaly 736
in anorexia nervosa (Rapid communication) 22
Adiposity
cortisol and the metabolic syndrome 500
precocious pubarche and 372
Adolescence
blood pressure in CAH 589
BMD in thalassaemia 273
bone loss in Cushing's disease 302
constitutional delay in boys 267
pituitary adenomas in 519
Adrenal incidentaloma
subclinical hypercortisolism and BMD 72
Age
leptin and IGF-I system in control population 213
responsiveness to GH therapy in ageing 238
Alendrolate
therapy, and VDR genotypes 365
Androgenaemia
adiposity and precocious pubarche 372
Androgens
adrenal secretion, and GH therapy 601
HRT in women (Review) 249
in patients with erectile dysfunction 632
Anorexia nervosa
adiponectin in (Rapid communication) 22
Antibodies
blocking, and remission in Graves' disease 403
see also Autoantibodies
Aquaporin-2 (AQP-2)
in impaired water excretion (Review) 1
Arginine vasopressin (AVP)
in impaired water excretion (Review) 1
signal peptide mutation in AVP gene (Case report) 108
Aromatase
activity in men (Review) 529
Autoantibodies
guidelines for diagnosis and monitoring of thyroid disease (Commentary) 138
thyroid, and iodine deficiency 36

Blood pressure
in children and adolescents with 21-hydroxylase deficiency 589
plasma insulin and left ventricular mass 316
Body composition
GH therapy in Prader–Willi syndrome 653
leptin and IGF-I system in control population 213
leptin and incretins in hypopituitarism 65
Bone
BMD in acromegaly 725
BMD in Addison's disease 617
BMD and adrenal incidentalomas 72
BMD in male hypogonadism 691
BMD in primary hyperparathyrodism 348
BMD in thalassaemia 273
homeostasis and oestrogens in men (Review) 529
loss in Cushing's disease 302
resorption, effects of soy protein 704
Breast cancer
oestrogen and (Review) 249
Breath test
chylomicron remnant metabolism 415
Bromocriptine
dopamine agonist withdrawal policy and prolactinomas (Letter) 111

© 2003 Blackwell Publishing Ltd

Cabergoline
dopamine agonist withdrawal policy and prolactinomas (Letter) 111
therapy of giant prolactinomas 662
CAH
blood pressure in children and adolescents 589
Calcitonin
guidelines for diagnosis and monitoring of thyroid disease (Commentary) 138
Calcitriol
vitamin D3 hydroxylases in fetal intestine 489
Calcium
CaR gene in familial hypocalciuric hypercalcaemia 199
Cancers
inhibin B and chemotherapy in children 296
see also Specific tumours
Cardiomyopathy, acromegalic 169
Cardiovascular risk
cortisol and the metabolic syndrome 500
lipid metabolism and oestrogens in men (Review) 529
oestrogen and (Review) 249
Chemotherapy
gonadotoxicity in children 296
Children
blood pressure in CAH 589
BMD in thalassaemia 273
combined pituitary hormone deficiency 785
Cushing's syndrome secondary to topical corticosteroid abuse (Letter) 795
fat distribution and precocious pubarche 372
inhibin B, chemotherapy and gonadotoxicity 296
leptin and SHBG in lymphoblastic leukaemia 770
MRI abnormalities in response to GH therapy 647
outcome of hyperinsulinism of infancy 355
testosterone therapy for CDGA in boys 267
urinary leptin measurement 78
uterine growth in Turner's syndrome 446
Cholesterol
effects of tibolone on HDL-cholesterol 49
metabolism, and oestrogens in men (Review) 529
Cholesteryl transfer protein
in hypothyroidism 581
Chylomicron remnants
metabolism in postmenopausal women 415
Circadian rhythm, of leptin 482
Cognition
oestrogen and (Review) 249
Constitutional delay in growth and adolescence (CDGA)
testosterone therapy 267
Corticosteroid-binding globulin
deficiency in a Brazilian kindred 756
Cortisol
bone loss in Cushing's disease 302
in the metabolic syndrome 500
CRH test
in ACTH-dependent Cushing's syndrome 718
pituitary apoplexy in Cushing's disease 545 (Commentary) 543
Cushing's disease/syndrome
ACTH-dependent, CRH test 718
bone loss in 302
CRH-induced pituitary apoplexy in 545 (Commentary) 543
leptin and GH in 220
secondary to topical corticosteroid abuse (Letter) 795
Cyproterone acetate
in treatment of acne (Letter) 246
Cytokines
profile in Graves' ophthalmopathy 280
Cytology
guidelines for diagnosis and monitoring of thyroid disease (Commentary) 138
guidelines for management of thyroid cancer (Commentary) 400

Dexamethasone
leptin and SHBG in ALL children 770
Diabetes mellitus
risk, in hyperinsulinism of infancy 355
type 1, and GH therapy in GHD 309
type 2, and chylomicron remnant metabolism 415
Diet
low-iodide 428
soy protein containing isoflavones 704
Dopamine agonists
therapy for acromegaly (Review) 387
therapy of giant prolactinomas 662
withdrawal policy and prolactinomas (Letter) 111

Elderly patients
GH treatment 99
Endometrial carcinoma
responses to progestogen 696
Erectile dysfunction
androgens and response to sildenafil 632
Ethnicity
testosterone levels and 262

Facial disfigurement
in Graves' ophthalmopathy 192
Fat distribution see Adiposity

Ferritin
insulin resistance syndrome and gender 380
Fertility
in spinal cord injured men 177
Fetus
vitamin D_3 hydroxylases in intestine 489
Fibroblast growth factor-2 (FGF-2)
in pituitary tumours 141
Fine-needle aspiration (FNA)
guidelines for diagnosis and monitoring of thyroid disease (Commentary) 138
guidelines for management of thyroid cancer (Commentary) 400

Gall-bladder disease
in medical therapy of acromegaly (Review) 387
Gender
effect on BMD in acromegaly 725
ferritin and insulin resistance syndrome 380
leptin and GH therapy in GHD 482
leptin and IGF-I system in control population 213
sex steroids and the insulin resistance syndrome 562
Genetics
alendrolate therapy and VDR genotypes 365
CaR gene in familial hypocalciuric hypercalcaemia 199
carriers for type II 3B-hydroxysteroid dehydrogenase deficiency 323
combined pituitary hormone deficiency in children 785
corticosteroid-binding globulin deficiency 756
CTLA4 gene and Graves' disease 732
guidelines for management of thyroid cancer (Commentary) 400
hTERT in parathyroid tumours 43
MEN-1 mutations in familial isolated primary hyperparathyroidism 639
MEN-2A in Chinese families 528
molecular analysis of 5_-reductase deficiency 627
molecular analysis of 21-hydroxylase gene (Letter) 247
PRKAR1A in pituitary adenomas 464
PTTG, PBF, FGF-2 and FGF-R-1 in pituitary tumours 141
PTTG in endocrine cancer (Review) 673
PTTG in pituitary adenomas 151
PTTG in pituitary tumours (Review) 673
PTTG in thyroid tumours (Review) 673
ret proto-oncogene, guidelines for diagnosis and monitoring of thyroid disease (Commentary) 138
signal peptide mutation in AVP gene (Case report) 108
tertiary hyperparathyroidism in XLH 163
thyroxine-binding globulin deficiency 409
vitamin D_3 hydroxylases in fetal intestine 489

GH
in Cushing's syndrome and simple obesity 220
effects of 6-weekly Sandostatin LAR in acromegaly 288
predicting the response to therapy 229
receptor antagonists and acromegaly (Review) 387
responsiveness to therapy in aging 238
-secreting pituitary adenomas, preoperative lanreotide 471
-secreting pituitary adenomas, tumorigenesis 464
secretogogue NN703 in GH-deficient adults 572
therapy, and adrenal androgen secretion 601
therapy, leptin and gender in GHD 482
therapy in Prader–Willi syndrome 653
therapy, re-assessment of GHD 456
therapy response in GHD, MRI abnormalities 647
therapy in type 1 diabetes 309
treatment in the elderly 99
GHD
adult health status measures 436
childhood-onset, re-assessment 456
diagnosis after pituitary surgery 156
GH secretogogue NN703 in adults 572
GH therapy in type 1 diabetes 309
leptin, gender and GH therapy 482
MRI abnormalities in response to GH therapy 647
testing for, in adults (Commentary) 18
Ghrelin
influence of acetylcholine in humans 92
GHRH
acipimox/GHRH test in diagnosis of GHD 156
in human illness, Prader–Willi syndrome and obesity 743
Glucocorticoids
Cushing's syndrome secondary to topical abuse (Letter) 795
leptin and SHBG in ALL children 770
therapy in Addison's disease 617
Glucose homeostasis
IGF system and 777
in medical therapy of acromegaly (Review) 387
Glycogen storage disease
type 1, growth in 332
Gonadotoxicity
chemotherapy in children 296
Gonadotrophins
progesterone receptor-mediated suppression in men 506
Graves' disease
blocking antibodies and remission in 403
CTLA4 gene and 732
facial disfigurement in ophthalmopathy 192

psychological factors in prognosis of hyperthyroidism 550
TSH-R and cytokine expression in ophthalmopathy 280
Growth
constitutional delay in boys 267
regulation in glycogen storage disease type 1 332
Gubbio study
plasma insulin and left ventricular mass 316
Guidelines
diagnosis and monitoring of thyroid disease (Commentary) 138
management of thyroid cancer (Commentary) 400

HCV-related liver cirrhosis 207
Health status measures
in adult GHD 436
Heart function
acromegalic cardiomyopathy 169
plasma insulin and left ventricular mass 316
Height
testosterone therapy for CDGA in boys 267
see also Stature; short
Hepatic lipase
effects of tibolone 49
Hepatocellular carcinoma
serum reverse triiodothyronine levels in 207
Hip replacement
GH treatment in the elderly 99
HRT
ACE activity in postmenopausal women 30
current controversies (Review) 249
oestrogen in Turner's syndrome 446
21-Hydroxylase deficiency
blood pressure in children and adolescents 589
molecular analysis of gene (Letter) 247
17β-Hydroxysteroid dehydrogenase
activity in men (Review) 529
response to progestogen in endometrial carcinoma 696
3β-Hydroxysteroid dehydrogenase deficiency (type II)
identification of carriers 323
Hyperadiponectinaemia
in anorexia nervosa (Rapid communication) 22
Hypercalcaemia
familial hypocalciuric (FHH), mutations in the CaR gene 199
Hypercortisolism
BMD and adrenal incidentalomas 72
Hyperinsulinism of infancy
risk of diabetes 355
Hyperparathyroidism
familial isolated primary, MEN-1 mutations in 639
primary, BMD in 348
tertiary, in XLH 163
Hyperprolactinaemia
due to macroprolactins (Commentary) 683
in hypothyroidism 185
Hypertension
plasma insulin and left ventricular mass 316
Hyperthyroidism
psychological factors in prognosis 550
Hypocalciuric hypercalcaemia, familial (FHH)
mutations in the CaR gene 199
Hypogonadism
effect on BMD in acromegaly 725
male, and BMD 691
Hypogonadotropism
in spinal cord injured men 177
Hypophosphataemia
osteomalacia and muscle weakness treated by surgery (Letter) 796
Hypophosphataemic rickets
X-linked, and tertiary hyperparathyroidism 163
Hypopituitarism
GH therapy, and adrenal androgen secretion 601
leptin and incretins in 65
Hypothalamic-pituitary axis
MRI abnormalities and response to GH in GHD children 647
Hypothalamic-pituitary-gonadal axis
oestrogens in men (Review) 529
Hypothalamic-pituitary-testis axis
in spinal cord injured men 177
Hypothyroidism
congenital, guidelines for diagnosis and monitoring of thyroid disease (Commentary) 138
hyperprolactinaemia in 185
low cholesteryl transfer protein in 581
maternal, and thyroid function 612
remnant-like particles in 617

IGF-I
in predicting the response to GH therapy 229
responsiveness to GH in aging 238
system, in control population 213
system, and glucose homeostasis 777
in thalassaemia 273
Illness
hypothalamic GHRH in 743
Incidentaloma, adrenal 72
Incretins
in hypopituitarism 65

Inhibins
chemotherapy and gonadotoxicity in children 296
clinical advances in reproductive medicine (Review) 115
Insulin
plasma, and left ventricular mass 316
resistance, in acromegaly 736
sensitivity, and IGF-I system 777
Insulinaemia
adiposity and precocious pubarche 372
Insulin resistance syndrome
ferritin and gender 380
sex steroids and transsexuals 562
Iodide
low dietary, and radioiodide thyroid ablation 428
Iodine
deficiency, and thyroid autoantibodies 36
sufficiency in maternal hypothyroidism 612
urinary, guidelines for diagnosis and monitoring of thyroid disease (Commentary) 138
Isoflavones
effects on lipids and bone resorption 704

Laboratory medicine practice guidelines
diagnosis and monitoring of thyroid disease (Commentary) 138
Lanreotide
preoperative, for GH-secreting pituitary adenomas 471
primary medical therapy for acromegaly (Review) 387
Leptin
in acromegaly 736
in children with lymphoblastic leukaemia 770
in control population 213
in Cushing's syndrome and obesity 220
gender and GH therapy in GHD 482
in hypopituitarism 65
urinary, in children 78
Lipids
effects of soy proteins 704
metabolism, and oestrogens in men (Review) 529
Lipoproteins
low cholesteryl transfer protein in hypothyroidism 581
Liver cirrhosis
HCV-related 207
Lymphoblastic leukaemia
leptin and SHBG in children 770

Macroprolactin
in hyperprolactinaemia (Commentary) 683
Macroprolactinaemia
detection by ultrafiltration 686
Matrix metalloproteinase 9 (MMP-9)
preoperative, and thyroid cancer 513
Men
BMD in hypogonadism 691
cabergoline therapy of giant prolactinomas 662
ferritin and insulin resistance syndrome 380
importance of oestrogens (Review) 529
progesterone receptor-mediated gonadotrophin suppression 506
spinal cord injury, endocrine profiles and semen quality 177
testosterone and ethnicity 262
testosterone and SHBG rhythms 710
Menopause
TSH in 340
Menstrual function
hyperprolactinaemia in hypothyroidism 185
Metabolic syndrome
cortisol and 500
Metabolism
bone, in Cushing's disease 302
bone, and oestrogens in men (Review) 529
chylomicron remnant, in postmenopausal women 415
lipids, and oestrogens in men (Review) 529
low cholesteryl transfer protein in hypothyroidism 581
remnant-like particles in hypothyroidism 617
MRI
growth response to GH in GHD children 647
Multiple endocrine neoplasia (MEN)
type 1, mutations in familial isolated primary hyperparathyroidism 639
type 2A, in Chinese families 528
types 1 and 2, management guidelines (Commentary) 400
Muscle weakness
hypophosphataemia and osteomalacia treated by surgery (Letter) 796

Neurokinin B
in normal pregnancy 597

Obesity
hypothalamic GHRH in 743
leptin and GH in 220
leptin and incretins in hypopituitarism 65
Octreotide
6-weekly Sandostatin LAR in acromegaly 288
reversal of acromegalic cardiomyopathy 169
therapy for acromegaly (Review) 387
Oestrogens
HRT and ACE activity in postmenopausal women 30

HRT, current controversies (Review) 249
HRT in Turner's syndrome 446
importance in males (Review) 529
receptors (Review) 529
thrombosis and (Review) 249
Ophthalmopathy Graves'
facial disfigurement in 192
TSH-R and cytokine expression in 280
Osteomalacia
hypophosphataemia and muscle weakness treated by surgery (Letter) 796
Osteoporosis
alendrolate therapy and VDR genotypes 365
Ovarian function
inhibins and activins (Review) 115

Parathyroidectomy
BMD in primary hyperparathyroidism 348
Parathyroid tumours
hTERT in 43
Pegvisomant
in medical therapy of acromegaly (Review) 387
Phosphate treatment
tertiary hyperparathyroidism in XLH 163
Phyto-oestrogens
HRT in women (Review) 249
Pituitary adenomas
GH-secreting and preoperative lanreotide 471
infrequent inactivation of PRKAR1A 464
non-functioning, ACTH immunopositive 59
non-functioning, markers of regrowth 763
PBF, FGF-2 and FGF-R-1 in 141
PTTG in 141, 151
in teenagers 519
Pituitary apoplexy
CRH-induced, in Cushing's disease 545 (Commentary) 543
Pituitary disease
combined pituitary hormone deficiency in children 785
Pituitary tumours
PTTG in (Review) 673
Pituitary tumour transforming gene (PTTG)
in endocrine cancer (Review) 673
in pituitary tumours 141, 151, 673
Prader–Willi syndrome
body composition and GH therapy 653
hypothalamic GHRH in 743
Prednisolone
leptin and SHBG in ALL children 770
Prednisone
therapy in Addison's disease 617
Pregnancy
inhibins and activins (Review) 115
neurokinin B in 597
thyroid function in maternal hypothyroidism 612
Progesterone
HRT, current controversies (Review) 249
receptor-mediated gonadotrophin suppression in men 506
Progesterone receptor
response to progestogen in endometrial carcinoma 696
Progestins
in HRT (Review) 249
Progestogen
HRT and ACE activity in postmenopausal women 30
responses, in endometrial carcinoma 696
Prolactin
detection of macroprolactinaemia by ultrafiltration 686
hyperprolactinaemia due to macroprolactins (Commentary) 683
Prolactinoma
dopamine agonist withdrawal policy (Letter) 111
giant, cabergoline therapy in men 662
Proto-oncogene
ret, guidelines for diagnosis and monitoring of thyroid disease (Commentary) 138
Psychological factors
prognosis of hyperthyroidism 550
Pubarche
precocious, and fat distribution 372

Radioiodine
feasibility of RCT in thyroid cancer 451
guidelines for management of thyroid cancer (Commentary) 400
therapy of thyroid papillary carcinoma 421
thyroid ablation and low-iodide diet 428
Radiotherapy
in acromegaly (Commentary) 128, 132, 136
5_-Reductase deficiency
molecular analysis 627
Remnant-like particles
in hypothyroidism 617
Reproductive medicine
inhibins and activins, clinical advances (Review) 115
Resistin
in acromegaly 736
Rickets, hypophosphataemic 163

Sandostatin LAR
6-weekly injection in acromegaly 288
primary medical therapy for acromegaly (Review) 387

Semen quality
in spinal cord injured men 177
SERMs
HRT in women (Review) 249
Sex hormone-binding globulin (SHBG)
in children with lymphoblastic leukaemia 770
rhythms in men 710
Sex see Gender, Men, Women
Sex steroids
insulin resistance syndrome in transsexuals 562
Sildenafil
in patients with erectile dysfunction 632
Somatostatin analogues
reversal of acromegalic cardiomyopathy 169
therapy for acromegaly (Review) 387
see also Lanreotide, Sandostatin LAR
Soy protein
effects on lipids and bone resorption 704
Spinal cord injury
endocrine profiles and semen quality 177
Stature, short
predicting the response to GH therapy 229
SWAN
TSH and menopause 340

Teenagers see Adolescents
Telomerase activity
hTERT in parathyroid tumours 43
Testicular function
inhibins (Review) 115
Testosterone
ethnicity and 262
in patients with erectile dysfunction 632
rhythms in men 710
therapy, and BMD in male hypogonadism 691
therapy for CDGA in boys 267
β-Thalassaemia
BMD in children and adolescents 273
Thiamazole
in Graves' disease 403
Thrombosis
oestrogen and (Review) 249
Thyroglobulin
guidelines for diagnosis and monitoring of disease (Commentary) 138
guidelines for management of thyroid cancer (Commentary) 400
in maternal hypothyroidism 612
in radioiodine therapy of thyroid carcinoma 421
rhTSH/thyroglobulin test in thyroid cancer 556
Thyroid carcinoma
feasibility of RCT for radioiodine therapy 451
guidelines for diagnosis and monitoring of disease (Commentary) 138
guidelines for management (Commentary) 400
low-iodide diet and radioiodide ablation 428
medullary, management guidelines (Commentary) 400
preoperative VEGF and MMP-9 513
PTTG in (Review) 673
radioiodine therapy with Tg(plus)/WBS(minus) 421
rhTSH/thyroglobulin test 556
Thyroidectomy
guidelines for management of thyroid cancer (Commentary) 400
Thyroid function
blocking antibodies in Graves' disease 403
first-line tests (Commentary) 20
guidelines for diagnosis and monitoring (Commentary) 138
hepatocellular carcinoma and HCV-related liver cirrhosis 207
in maternal hypothyroidism 612
thyroid autoantibodies and iodine deficiency 36
Thyroxine
guidelines for diagnosis and monitoring disease (Commentary) 138
in maternal hypothyroidism 612
therapy, and remnant-like particles in hypothyroidism 617
Thyroxine-binding globulin
deficiency, in Taiwan 409
Tibolone
effects on HDL-cholesterol 49
HRT in women (Review) 249
Transsexuals
sex steroids and the insulin resistance syndrome 562
Triiodothyronine
guidelines for diagnosis and monitoring disease (Commentary) 138
in hepatocellular carcinoma 207
TSH
blocking antibodies in Graves' disease 403
first-line thyroid function tests (Commentary) 20
guidelines for diagnosis and monitoring of disease (Commentary) 138
guidelines for management of thyroid cancer (Commentary) 400
hyperprolactinaemia in hypothyroidism 185
menopausal status and 340
rhTSH/thyroglobulin test in thyroid cancer 556
TSH-R expression in Graves' ophthalmopathy 280

Turner's syndrome
uterine growth in 446

Ultrafiltration
detection of macroprolactinaemia 686
Ultrasound
uterine growth in Turner's syndrome 446
Urine
iodine, guidelines for diagnosis and monitoring of thyroid disease (Commentary) 138
leptin measurement in children 78
Uterine growth
in Turner's syndrome 446

Vascular endothelial growth factor (VEGF)
preoperative, and thyroid cancer 513
Vasopressin see Arginine vasopressin
Vitamin D
alendrolate therapy and VDR genotypes 365
D_3 hydroxylases in fetal intestine 489

Water excretion
impaired, and AVP and AQP-2 (Review) 1
Whole body scan
radioiodine therapy of thyroid carcinoma 421
Women
alendrolate therapy and VDR genotypes 365
chylomicron remnant metabolism 415
effects of soy protein on lipids and bone resorption 704
ferritin and insulin resistance syndrome 380
HRT and ACE activity 30
HRT, current controversies (Review) 249
neurokinin B in normal pregnancy 597
tibolone and HDL-cholesterol 49
TSH and menopausal status 340